Breast Cancer Index Test Data Reinforces Efficacy
Hologic and Biotheranostics unveiled new data showing that the Breast Cancer Index (BCI) test improves treatment decision-making.
Hologic and Biotheranostics unveiled new data showing that the Breast Cancer Index (BCI) test improves treatment decision-making.
BD, a global medical tech company, announced U.S. FDA market approval for the BD Onclarity HPV Assay to be used with the ThinPrep Pap Test.
The Aptima SARS-CoV-2/Flu Assay from Hologic tests simultaneously for SARS-CoV-2, influenza A, and influenza B on the Panther molecular diagnostics system.
Biotheranostics is a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers.
Read MoreHologic’s Aptima HIV-1 Quant Dx assay is now the first dual-claim assay for both diagnosis and viral load monitoring in the United States.
Read MoreGenius Digital Diagnostics is the first digital cytology platform to combine a new artificial intelligence algorithm with advanced digital imaging to help identify precancerous lesions and cancer cells.
Read MoreThis investment will enable Hologic to expand production capacity to 13 million covid-19 tests per month by January 2022.
Read MoreTwo FDA-approved molecular testing platforms are leading to better targeted treatments for this common infection.
Read MoreThe assay is now authorized for asymptomatic individuals and symptomatic sample pooling.
Read MoreUnder the contract, Hologic will expand production of custom sample collection and processing consumables for covid-19 tests.
Read MoreBy testing samples from multiple individuals simultaneously, pooling may help laboratories deliver accurate molecular test results more quickly.
Read MoreThe 2020 ServiceTrak Clinical Laboratory Awards are based on interviews with respondents in 2,229 clinical testing locations having 5,117 instruments.
Read MoreAdvaMed has created a comprehensive, national covid-19 diagnostic supply registry to help state and federal governments in their pandemic responses.
Read MoreAvero will support the diagnostic needs of hospitals, health systems, multispecialty family practices, urgent care centers, and county health departments.
Read MoreFDA has issued emergency use authorizations to Hologic for its Panther Fusion SARS-CoV-2 assay and to LabCorp for its Covid-19 RT-PCR test.
Read MoreHospital, public health, and reference laboratories can perform the test on Hologic’s Panther Fusion system, a fully automated, high-throughput molecular diagnostic platform that is widely used across the United States.
Read MoreA COVID-19 diagnostic designed for use on a system that can process up to 1,000 tests in 24 hours will receive advanced development support from an HHS BARDA grant.
Read MoreImproved accuracy in identifying bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis will enable better targeted treatment for women.
Read More